参考文献/References:
[1] Saez-Ibanez AR,Upadhaya S,Partridge T,et al. Landscape of cancer cell therapies:trends and real-world data[J]. Nat Rev Drug Discov,2022,21(9):631-632.
[2] Huang R,Li X,He Y,et al. Recent advances in CAR-T cell engineering[J]. J Hematol Oncol,2020,13(1):86.
[3] Locke FL,Ghobadi A,Jacobson CA,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1):a single-arm,multicentre,phase 1-2 trial[J]. Lancet Oncol,2019,20(1):31-42.
[4] 韦楠,陈天平,刘洪军. 嵌合抗原受体T细胞在儿童复发难治性急性淋巴细胞白血病中的研究进展[J]. 中国当代儿科杂志,2023,25(2):210-216.
[5] Chmielewski M,Abken H. TRUCKS,the fourth‐generation CAR T cells:current developments and clinical translation[J]. Adv Cell Gene Ther,2020,3(3):e84.
[6] Ragoonanan D,Sheikh IN,Gupta S,et al. The evolution of chimeric antigen receptor T-Cell therapy in children,adolescents and young adults with acute lymphoblastic leukemia[J]. Biomedicines,2022,10(9):2286.
[7] Xie B,Li Z,Zhou J,et al. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies[J]. Cancers(Basel),2022,14(13):3230.
[8] 董佳艺,陈斯泽,邵丽娟,等. 嵌合抗原受体T细胞疗法联合免疫调节剂治疗实体瘤研究进展[J]. 实用医学杂志,2022,38(21):2643-2648.
[9] Li W,Qiu S,Chen J,et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy[J]. Immunity,2020,53(2):456-470.e6.
[10] Daei Sorkhabi A,Mohamed Khosroshahi L,Sarkesh A,et al. The current landscape of CAR T-cell therapy for solid tumors:mechanisms,research progress,challenges,and counterstrategies[J]. Front Immunol,2023,14:1113882.
[11] Maldini CR,Claiborne DT,Okawa K,et al. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo[J]. Nat Med,2020,26(11):1776-1787.
[12] Zhang B,Wang Y,Yuan Y,et al. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells[J]. Ann Rheum Dis,2021,80(2):176-184.
[13] Sicard A,Lamarche C,Speck M,et al. Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients[J]. Am J Transplant,2020,20(6):1562-1573.
[14] Amor C,Feucht J,Leibold J,et al. Senolytic CAR T cells reverse senescence-associated pathologies[J]. Nature,2020,583(7814):127-132.
[15] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志,2022,37(6):553-578.
[16] Lopez B,Ravassa S,Moreno MU,et al. Diffuse myocardial fibrosis:mechanisms,diagnosis and therapeutic approaches[J]. Nat Rev Cardiol,2021,18(7):479-498.
[17] Webber M,Jackson SP,Moon JC,et al. Myocardial fibrosis in heart failure:anti-fibrotic therapies and the role of cardiovascular magnetic resonance in drug trials[J]. Cardiol Ther,2020,9(2):363-376.
[18] Wang Y,Wang M,Samuel CS,et al. Preclinical rodent models of cardiac fibrosis[J]. Br J Pharmacol,2022,179(5):882-899.
[19] de Boer RA,de Keulenaer G,Bauersachs J,et al. Towards better definition,quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology[J]. Eur J Heart Fail,2019,21(3):272-285.
[20] Liu M,Lopez de Juan Abad B,Cheng K. Cardiac fibrosis:myofibroblast-mediated pathological regulation and drug delivery strategies[J]. Adv Drug Deliv Rev,2021,173:504-519.
[21] Bugg D,Bailey LRJ,Bretherton RC,et al. MBNL1 drives dynamic transitions between fibroblasts and myofibroblasts in cardiac wound healing[J]. Cell Stem Cell,2022,29(3):419-433.e10.
[22] Aghajanian H,Kimura T,Rurik JG,et al. Targeting cardiac fibrosis with engineered T cells[J]. Nature,2019,573(7774):430-433.
[23] Rodriguez Garcia A,Palazon A,Noguera-Ortega E,et al. CAR-T Cells hit the tumor microenvironment:strategies to overcome tumor escape[J]. Front Immunol,2020,11:1109.
[24] Rurik JG,Tombacz I,Yadegari A,et al. CAR T cells produced in vivo to treat cardiac injury[J]. Science,2022,375(6576):91-96.
[25] Franco F,Jaccard A,Romero P,et al. Metabolic and epigenetic regulation of T-cell exhaustion[J]. Nat Metab,2020,2(10):1001-1012.
[26] Wang LC,Lo A,Scholler J,et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity[J]. Cancer Immunol Res,2014,2(2):154-166.
[27] 杨迪雅,孔祥辉,周秀梅. 嵌合抗原受体疗法在肿瘤免疫治疗中的研究进展[J]. 中国细胞生物学学报,2023,45(3):557-568.
[28] Han MY,Liu ZX,Liu L,et al. Dual genetic tracing reveals a unique fibroblast subpopulation modulating cardiac fibrosis[J]. Nat Genet,2023,55(4):665-678.
[29] Wang Z,Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J]. Biomark Res,2018,6:4.
[30] Zhou JE,Sun L,Jia Y,et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo[J]. J Control Release,2022,350:298-307.
[31] Sun Y,Ma M,Cao D,et al. Inhibition of fap promotes cardiac repair by stabilizing BNP[J]. Circ Res,2023,132(5):586-600.
[32] Sun S,Hao H,Yang G,et al. Immunotherapy with CAR-modified T cells:toxicities and overcoming strategies[J]. J Immunol Res,2018,2018:2386187.
[33] Zheng Y,Nandakumar KS,Cheng KS. Optimization of CAR-T cell-based therapies using small-molecule-based safety switches[J]. J Med Chem,2021,64(14):9577-9591.
[34] Moretti A,Ponzo M,Nicolette CA,et al. The past,present,and future of non-viral CAR T cells[J]. Front Immunol,2022,13:867013.